A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetes Mellitus, Type 1

In brief

The purpose of this research study is to look at concentrations of GSK189075 in blood when single doses of the drug are taken by mouth in combination with basal insulin. The clinical effects of the drug in combination with insulin on the body will also be studied. The results will help determine doses of GSK189075 can be studied in the future in the type I diabetes mellitus population.

Key facts

Study ID

NCT00575159

Run by

GlaxoSmithKline

People needed

10

Starts

2008-03-31

Expected to finish

2008-12-18

Last updated by the study team

2017-10-09

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult male/female, 18 to 55 years old
• Diagnosis of type 1 diabetes mellitus for at least 6 months; and using a continuous insulin pump
• Willing and able to follow all study-related instructions provided by the site staff.
• Willing to provide signed informed consent.

You may not qualify if…

• Pregnant or a nursing female.
• Have a past or current disease such as heart, liver, kidney, blood, brain, or other disease.
• Have HIV or hepatitis, or have alcohol or drugs in your system at the screening visit.
• Have a history of alcohol abuse or have an eating disorder
• Have been in another research study in the last month or have taken certain medications in the 1 week before study drug would be taken.

Where it is running

• GSK Investigational Site — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.